by clinical trials*

Learn more

The Braster system offers
a chance for detecting alarming
changes at a very early stage,
which means:

  • less invasive
    and shorter treatment
  • faster recovery

* Prospective observational studies on a group of 1340 women conducted in reference centers for breast cancer diagnostics in Poland from 2009-2016.

Efficacy confirmed by clinical trials

The Braster medical device was created in cooperation with Polish specialists from the best research centers. Thanks to their knowledge of i.a. liquid crystal technologies, optoelectronics, and artificial intelligence, we were able to create a system that has the potential to become an important tool in breast cancer prophylaxis for women around the world. Together, we also conducted successful clinical trials*

* Observational studies conducted in Poland on a group of over 1500 women from 2013-2016.

Braster holds TUV NORD certificates in quality management systems, the main advantage of which is improvement of quality and services and a reduced risk of complaints.

The Braster System is a medical product meeting the requirements of the Council Directive 93/42/EEC (CE marking).

Learn more
  • Saska Kepa Medical Center

    ul. Marokanska 16, 03-977 (ThermaMED and Innomed)

  • Magodent

    ul. Fieldorfa 40, 01-999 (ThermaMED)

  • Lower Silesian Center of Oncology

    pl. Hirszfelda 16, 53-416 (ThermaALG, ThermaMED and Innomed)

  • Femina Medical Center

    ul. Kłodnicka 23, 40-703 (ThermaMED)

  • Specialist Medical Center for Minimally Invasive Surgery SCM Sp. z o.o.

    ul. Grzegorzecka 67c/U6, 31-559 (ThermaALG)

  • Independent Public Health Care Center University Hospital (Collegium Medicum Jagiellonian University)

    ul. Kopernika 36, 31-501

  • Zdrowie Kobiety Sp. z o.o.

    ul. Praska 30 C, 30-328 (ThermaALG)

Key conclusions from the ThermaALG observational study:

  • The efficacy and usefulness of the Braster medical device for detecting pathologies in the mammary gland was confirmed
  • In women below 50 years of age, the sensitivity* of the method was 81.5% (95% CI: 64.1; 92.6), and its specificity** was 87% (95% CI: 79.7; 92.4)
  • The Braster medical device had 82% efficacy in detecting changes smaller than 2 cm
  • No impact of breast size or structure on efficacy of detecting lesions in the entire population of the examined women was found
  • The safety and non-invasiveness of the method were confirmed

* The likelihood of obtaining a positive result of the diagnostic test among ill patients. Higher sensitivity = overlooking fewer ill patients.

** The likelihood of obtaining a negative result of the diagnostic test among patients not suffering from the diagnosed disease. Higher specificity = fewer healthy patients incorrectly identified as ill.

Learn more

Experts opinion about
Braster medical device

Need more

Leave us your number.
We will call You back as soon
as possible to answer
your questions.

Please fill in the required fields correctly

Thank You for Your contact details.

We will contact You at the selected date and time

The form was not sent

The data have not been sent, because You did not consent to communication by phone.

The administrator of your data is BRASTER S.A. with its registered office in Szeligi, ul. Cichy Ogród 7 (05-850 Ożarów Mazowiecki). Your personal data will be processed in relation to your contact with BRASTER S.A. Data submission is voluntary, but we need them to contact you. You have the right to access your personal data and to correct them.

1 dzień 5 dni 1 miesiąc Okres od: do: Wolumen Kurs pl

Raty PayU to możliwość zapłacenia za zakupy w ratach (od 3 do nawet 36)

We use cookies to improve the quality of our service. Using our website without changing the cookie settings in your browser means that you agree to have them saved or used. You can find more information in the Privacy and Cookie Policy